These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9225 related articles for article (PubMed ID: 12773015)
1. Melanoma vaccines: early progress and future promises. Zarour HM; Kirkwood JM Semin Cutan Med Surg; 2003 Mar; 22(1):68-75. PubMed ID: 12773015 [TBL] [Abstract][Full Text] [Related]
2. Dendritic cell vaccines in melanoma: from promise to proof? Lesterhuis WJ; Aarntzen EH; De Vries IJ; Schuurhuis DH; Figdor CG; Adema GJ; Punt CJ Crit Rev Oncol Hematol; 2008 May; 66(2):118-34. PubMed ID: 18262431 [TBL] [Abstract][Full Text] [Related]
3. Antigen-based immunotherapy of melanoma: Canvaxin therapeutic polyvalent cancer vaccine. Hsueh EC; Morton DL Semin Cancer Biol; 2003 Dec; 13(6):401-7. PubMed ID: 15001158 [TBL] [Abstract][Full Text] [Related]
4. Dynamic changes of specific T cell responses to melanoma correlate with IL-2 administration. Andersen MH; Gehl J; Reker S; Pedersen LØ; Becker JC; Geertsen P; thor Straten P Semin Cancer Biol; 2003 Dec; 13(6):449-59. PubMed ID: 15001164 [TBL] [Abstract][Full Text] [Related]
5. Results of clinical trials with an allogenic melanoma tumor cell lysate vaccine: Melacine. Sondak VK; Sosman JA Semin Cancer Biol; 2003 Dec; 13(6):409-15. PubMed ID: 15001159 [TBL] [Abstract][Full Text] [Related]
6. Strategies to enhance the therapeutic activity of cancer vaccines: using melanoma as a model. Berinstein NL Ann N Y Acad Sci; 2009 Sep; 1174():107-17. PubMed ID: 19769743 [TBL] [Abstract][Full Text] [Related]
14. Vaccination: role in metastatic melanoma. Pilla L; Valenti R; Marrari A; Patuzzo R; Santinami M; Parmiani G; Rivoltini L Expert Rev Anticancer Ther; 2006 Aug; 6(8):1305-18. PubMed ID: 16925496 [TBL] [Abstract][Full Text] [Related]
15. Evaluation of melanoma vaccines with molecularly defined antigens by ex vivo monitoring of tumor-specific T cells. Speiser DE; Pittet MJ; Rimoldi D; Guillaume P; Luescher IF; Liénard D; Lejeune F; Cerottini JC; Romero P Semin Cancer Biol; 2003 Dec; 13(6):461-72. PubMed ID: 15001165 [TBL] [Abstract][Full Text] [Related]
16. Blood dendritic cells generated with Flt3 ligand and CD40 ligand prime CD8+ T cells efficiently in cancer patients. Davis ID; Chen Q; Morris L; Quirk J; Stanley M; Tavarnesi ML; Parente P; Cavicchiolo T; Hopkins W; Jackson H; Dimopoulos N; Tai TY; MacGregor D; Browning J; Svobodova S; Caron D; Maraskovsky E; Old LJ; Chen W; Cebon J J Immunother; 2006; 29(5):499-511. PubMed ID: 16971806 [TBL] [Abstract][Full Text] [Related]
17. [General principles and first clinical trials of therapeutic vaccines against cancer]. Baurain JF; Van der Bruggen P; Van den Eynde BJ; Coulie PG; Van Baren N Bull Cancer; 2008 Mar; 95(3):327-35. PubMed ID: 18390413 [TBL] [Abstract][Full Text] [Related]
18. Immune responses in the draining lymph nodes against cancer: implications for immunotherapy. Shu S; Cochran AJ; Huang RR; Morton DL; Maecker HT Cancer Metastasis Rev; 2006 Jun; 25(2):233-42. PubMed ID: 16770535 [TBL] [Abstract][Full Text] [Related]
20. Allogeneic and autologous melanoma vaccines: where have we been and where are we going? Sondak VK; Sabel MS; Mulé JJ Clin Cancer Res; 2006 Apr; 12(7 Pt 2):2337s-2341s. PubMed ID: 16609055 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]